12 Feb [146] Apixaban is safer and more effective than rivaroxaban for non-valvular atrial fibrillation
Abstract Background: Non-valvular atrial fibrillation (NVAF) poses risks of mortality and thromboembolic events, necessitating anticoagulant therapy. Direct oral anticoagulants (DOACs) such as apixaban and dabigatran have emerged as alternatives to warfarin due to their convenience. Choosing...
